Analyst firms · Truist Securities · CORT

Truist Securities CORT price target and rating history

Corcept Therapeutics Incorporated (CORT) · Health Care

Truist Securities rates Corcept Therapeutics Incorporated (CORT) Buy with a $164 price target, as of its latest action on Aug 18, 2026. It has published 4 rating actions on CORT since January 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Truist Securities's $164 is 128% above that.

Current rating
Buy
Price target
$164
Median target, all firms
$72
Actions on CORT
4

Truist Securities price target on CORT

$164$97$302023202420252026
Truist Securities price target on CORT, each point a stated target, January 2022 to August 2026.

Every Truist Securities rating on CORT

How other firms rate CORT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Truist SecuritiesBuy$164Aug 18, 2026
Wolfe ResearchUnderperform$50Jul 27, 2026
UBSBuy$72May 13, 2026

Questions about Truist Securities and CORT

What is Truist Securities's price target for CORT?
Truist Securities's latest stated price target for Corcept Therapeutics Incorporated (CORT) is $164, from its action on Aug 18, 2026.
What is Truist Securities's rating on CORT?
Truist Securities rates CORT Buy, a bullish rating, as of Aug 18, 2026.
When did Truist Securities last change its view on CORT?
On Aug 18, 2026, Truist Securities resumes coverage at Buy, price target $164.
How does Truist Securities's CORT target compare with other analysts?
Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Truist Securities's $164 is 128% above that.

More CORT rating histories

All Truist Securities ratingsCORT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.